Glenmark Pharmaceuticals Share Price: 51.0% CAGR in 3 Years, the Fastest in Its Group, Against Torrent Pharma and Zydus
- November 12, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Glenmark Pharmaceuticals Share Price: 51.0% CAGR in 3 Years, the Fastest in Its Group, Against Torrent Pharma and Zydus
Glenmark Pharmaceuticals previous close Rs 2,677.20. 3-year CAGR 51.0%. Up 3.4x since 10 Nov 2023. ROE 18.07%. Market cap Rs 75,495 crore.
Quick Answer
The Glenmark Pharmaceuticals share price closed at Rs 2,677.20 on 11 November 2026, a compounded annual return of 51.0% over three years. That compares with Torrent Pharmaceuticals at 32.3% and Zydus Lifesciences at 24.6%. The company has a market cap of Rs 75,495 crore and a P/E of 52.02 against an industry P/E of 40.71.
The Glenmark Pharmaceuticals share price has more than tripled in three years, which is the strongest return among the three drug makers compared here. Glenmark Pharmaceuticals, based in Mumbai, sells branded generics in India and generic medicines in the United States, Europe and other markets, with a focus on respiratory and skin care.
This article compares that run with Torrent Pharmaceuticals and Zydus Lifesciences. We calculate the three-year CAGR for all three and set the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Glenmark Pharmaceuticals Share Price Returned in 3 Years?
The Glenmark Pharmaceuticals stock closed at Rs 777.85 on 10 November 2023 and at Rs 2,677.20 on 11 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 3.44 lakh, which is a CAGR of 51.0%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Glenmark Pharmaceuticals can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Glenmark Pharmaceuticals share price has also followed the stronger performance of its branded business in India and its growing presence in respiratory and dermatology medicines.
Glenmark Pharmaceuticals vs Torrent Pharmaceuticals and Zydus Lifesciences: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 10 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 11 November 2026.
| Company | Close on 10 Nov 2023 | Previous close (11 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Glenmark Pharmaceuticals | Rs 777.85 | Rs 2,677.20 | 3.4x | 51.0% |
| Torrent Pharmaceuticals | Rs 2,058.20 | Rs 4,761.00 | 2.3x | 32.3% |
| Zydus Lifesciences | Rs 619.90 | Rs 1,199.50 | 1.9x | 24.6% |
The Glenmark Pharmaceuticals stock leads the group at 51.0%, followed by Torrent Pharmaceuticals at 32.3% and Zydus Lifesciences at 24.6%. Glenmark Pharmaceuticals leads the group, followed by Torrent Pharma and then Zydus. Glenmark is the smallest of the three by market cap, and it earns the highest ROE of the three.
Look at the Glenmark Pharmaceuticals share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals | Rs 1,81,169 crore | 86.32 | 40.71 | 11.42% | 0.77 |
| Zydus Lifesciences | Rs 1,18,713 crore | 27.59 | 40.71 | 15.10% | 0.50 |
| Glenmark Pharmaceuticals | Rs 75,495 crore | 52.02 | 40.71 | 18.07% | 0.13 |
By market cap, Torrent Pharmaceuticals is the largest of the group at Rs 1,81,169 crore, while the Glenmark Pharmaceuticals stock stands at Rs 75,495 crore, about 42% of that size. On earnings, Glenmark Pharmaceuticals shares trade at a P/E of 52.02 against an industry P/E of 40.71, a premium of about 28%, which signals that the market expects faster earnings growth. Peer multiples are Torrent Pharmaceuticals at 86.32 and Zydus Lifesciences at 27.59.
Return on equity is 18.07% for the Glenmark Pharmaceuticals stock, which ranks first among the three, and debt to equity stands at 0.13. Trailing EPS is Rs 51.42. A sharp rise in price can push a stock to a higher multiple, so the P/E should be read together with return on equity and the debt position.
What Is Driving the Glenmark Pharmaceuticals Stock?
Glenmark sells branded generics in India, with strength in respiratory care and dermatology, and it also sells generic medicines in the United States and Europe. It has invested in research on newer medicines in addition to its generic business.
The company carries low debt on its balance sheet. Its strong share price run has lifted its market cap and its P/E, so investors follow its quarterly numbers closely for signs that earnings are keeping pace.
Followers of the Glenmark Pharmaceuticals share price usually track growth of the India business, performance in the United States and Europe, research progress and operating margins.
How the Established Players Stack Up
Torrent Pharmaceuticals is an Ahmedabad-based drug maker from the Torrent Group with strength in cardiac and central nervous system medicines in India. It compounded at 32.3% a year, on a market cap of Rs 1,81,169 crore and an ROE of 11.42%.
Zydus Lifesciences is an Ahmedabad-based drug maker, formerly Cadila Healthcare, with generics, vaccines, biosimilars and a consumer wellness arm. It compounded at 24.6% a year, on a market cap of Rs 1,18,713 crore and an ROE of 15.10%.
What Should Investors Track Next?
Three things are worth watching on the Glenmark Pharmaceuticals share price. First, growth of the India branded business. Second, performance in the United States and Europe. Third, progress on research projects.
At a P/E of 52, the stock trades above the industry P/E of 41, and its debt to equity of 0.13 is low. A higher multiple leaves less room for disappointment, so follow quarterly numbers closely.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Glenmark Pharmaceuticals stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Glenmark Pharmaceuticals share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Glenmark Pharmaceuticals share price and compare pharma stocks live.
The Fastest Compounder in Its Group With the Highest ROE
The Glenmark Pharmaceuticals share price compounded at 51.0% a year over three years, ahead of Torrent Pharma at 32.3% and Zydus at 24.6%. Its ROE of 18.07% is the highest of the three and its debt to equity of 0.13 is low.
Zydus brings the lowest P/E, while Torrent Pharma brings the largest market cap and the highest multiple. The choice depends on whether you prefer the faster return or a lower multiple.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Glenmark Pharmaceuticals share price today?
Ans. Glenmark Pharmaceuticals closed at Rs 2,677.20 on 11 November 2026, according to NSE data. It has a market cap of Rs 75,495 crore and a P/E of 52.02. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Glenmark Pharmaceuticals stock?
Ans. Glenmark Pharmaceuticals delivered a price CAGR of 51.0% over three years, moving from Rs 777.85 on 10 November 2023 to Rs 2,677.20 on 11 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Glenmark better than Zydus?
Ans. Glenmark Pharmaceuticals delivered a higher three-year CAGR at 51.0% than Zydus at 24.6%. Zydus is larger by market cap at Rs 1,18,713 crore against Rs 75,495 crore and trades at a lower P/E of 27.59 against 52.02, while Glenmark has a higher ROE at 18.07% against 15.10%. The better choice depends on your view of each business.
What does Glenmark Pharmaceuticals do?
Ans. Glenmark Pharmaceuticals is a Mumbai-based drug maker that sells branded generics in India and generic medicines in the United States, Europe and other markets.
Is the Glenmark Pharmaceuticals stock debt free?
Ans. The debt to equity ratio of the Glenmark Pharmaceuticals stock is 0.13 and its return on equity is 18.07%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Glenmark Pharmaceuticals expensive compared with the industry?
Ans. Glenmark Pharmaceuticals trades at a P/E of 52.02 against an industry P/E of 40.71. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Glenmark Pharmaceuticals delivered the highest three-year CAGR at 51.0%, followed by Torrent Pharmaceuticals at 32.3%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.
